June 5, 2022Open Access

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

In this trial involving patients with HER2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the physician's choice of chemotherapy. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast04 ClinicalTrials.gov number, NCT03734029.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Shanu Modi

William Jacot

Toshinari Yamashita

Journals

New England Journal of Medicine

Actions

Institutions

University of California, San Francisco

Inserm

Memorial Sloan Kettering Cancer Center

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study